Skip to main content

Table 1 The intravenous taurolidine treatment did not impair the above mentioned blood parameters after 39 cycles (Wilcoxon test, p = not significant).

From: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case

Serum parameters Median Range
CA 72-4 (tumor marker, U/ml) 0.6 0.3–1.8
CEA (tumor marker, μg/l) 18.8 6.7–32.4
Leukocyte (/μl) 6.4 4.8–13.0
Hemoglobin (g/l) 13.0 10.4–14.8
Hemocrit (%) 40 32–44
Thrombocyte (103/μl) 225 171–321
Glucose (mg/dl) 94 54–283
Saline (mg/dl) 138 130–149
Potassium (mg/dl) 4.3 3.6–5.3
Creatinine (mg/dl) 1.1 0.74–1.75
Urea (mg/dl) 34 22–72
Protein (g/dl) 7.2 6.1–7.4
GOT (U/l) 23 7–95
GPT (U/l) 13 8–73
Total bilirubine (mg/dl) 0.3 0.1–0.6
Alkaline phosphatase (U/l) 70 56–122
Amylase (U/l) 53 44–104
Lipase (U/l) 17.5 17–18
INR 1.1 1.0–1.2